Skip to main content

Advertisement

SpringerLink
Log in

ER−/ER+ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

In this study, we established two PTX-resistant breast cancer cell lines, 231 TIM10 and MCF-7 TIM10, from ER-negative MDA-MB-231 cells and ER-positive MCF-7 cells by pulse selection, respectively. We found that 231 TIM10 variants acquired higher drug resistance than MCF-7 TIM10 variants by the pulse selection, although ER-positive MCF-7 cells were not as sensitive as ER-negative MDA-MB-231 to the initial pulses with PTX. 231 TIM10 had 11.9-fold greater resistance (RI = 11.9) than the parental MDA-MB-231 cells, while MCF-7 TIM10 got 5.5-fold resistance (RI = 5.5) when compared with the parental MCF-7 cells. In the presence of 5nM PTX, 231 TIM10 cells formed colonies, but no colony formed when MCF-7 TIM10 cells were cultured in the same condition. These data have two implications. First, the ER expression state might be an important determinant for the response of breast cancer cells to paclitaxel treatment. Second, ER-negative and ER-positive breast cancer cells develop drug-resistance phenotype with distinctive mechanisms. Our work not only established useful models for studying the paclitaxel resistance but also provides interesting clues to understand the mechanisms underlying the drug resistance of ER-negative and ER-positive breast cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Gluz O, et al. Triple-negative breast cancer—current status and future directions. Ann Oncol. 2009;20(12):1913–27.

    Article  PubMed  CAS  Google Scholar 

  2. Rose AA, Siegel PM. Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull Cancer. 2006;93(9):931–43.

    PubMed  CAS  Google Scholar 

  3. Hassan MS, Ansari J, Spooner D, Hussain SA. Chemotherapy for breast cancer (Review). Oncol Rep. 2010;24:1121–31.

    Article  PubMed  CAS  Google Scholar 

  4. Martinez VG, O’Connor R, Liang Y, Clynes M. CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance. Br J Cancer. 2008;98(3):564–70.

    Article  PubMed  CAS  Google Scholar 

  5. Lee DH, et al. Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells. J Proteome Res. 2010;9(11):5668–76.

    Article  PubMed  CAS  Google Scholar 

  6. Cheung CH, et al. Cancer cells acquire mitotic drug resistance properties through beta I-Tubulin mutations and alterations in the expression of beta-tubulin isotypes. PLoS One. 2010;5(9):e12564.

    Article  PubMed  Google Scholar 

  7. Berry DA, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1658–2356.

    Article  PubMed  CAS  Google Scholar 

  8. Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–717.

    Article  Google Scholar 

  9. Barrios CH, Sampaio C, Vinholes J, Caponero R. What is the role of chemotherapy in estrogen receptorpositive, advanced breast cancer? Ann Oncol. 2009;20:1157–62.

    Article  PubMed  CAS  Google Scholar 

  10. Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 2007;67(11):5337–44.

    Article  PubMed  CAS  Google Scholar 

  11. Tabuchi Y, et al. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol. 2009;34:313–9.

    PubMed  CAS  Google Scholar 

  12. Foulkes WD, et al. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.

    Article  PubMed  CAS  Google Scholar 

  13. Liedtke C, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–81.

    Article  PubMed  Google Scholar 

  14. Carey LA. Directed therapy of subtypes of triple-negative breast cancer. Oncol. 2010;15:49–56.

    CAS  Google Scholar 

  15. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer. Br Cancer. 2008;15:303–8.

    Article  Google Scholar 

  16. Kan N, Kuwata K, Mise K, Kodama H. Effective therapeutic regimens for patients with triple-negative (er/pgr/her2-negative) metastatic breast cancer. Gan To Kagaku Ryoho. 2010;37:1259–64.

    PubMed  Google Scholar 

  17. Yang LY, Trujillo JM. Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods. Cancer Res. 1990;50:3218–25.

    PubMed  CAS  Google Scholar 

  18. Glynn SA, et al. A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin. Br J Cancer. 2004;91(10):1800–7.

    Article  PubMed  CAS  Google Scholar 

  19. Brown I, et al. Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Br Cancer Res. 2004;6(5):601–7.

    Article  Google Scholar 

  20. Gan Y, Wientjes MG, Lu J, Au JL. Cytostatic and apoptotic effects of paclitaxel in human breast tumors. Cancer Chemother Pharmacol. 1998;42:177–82.

    Article  PubMed  CAS  Google Scholar 

  21. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality. Int J Cancer. 1999;83:151–6.

    Article  PubMed  CAS  Google Scholar 

  22. Giampietro G, et al. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Br Cancer Res Treat. 2007;101:355–65.

    Article  Google Scholar 

  23. Perez EA. Paclitaxel in breast cancer. Oncol. 1998;3:373–90.

    CAS  Google Scholar 

  24. Campone M, et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer. 2009;100:315–21.

    Article  PubMed  CAS  Google Scholar 

  25. Kwon YS, et al. Sensitive ChIP-DSL technology reveals an extensive estrogen receptor α-binding program on human gene promoters. PNAS. 2007;104(12):4852–7.

    Article  PubMed  CAS  Google Scholar 

  26. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor–regulated transcription. Cell. 2000;103:843–52.

    Article  PubMed  CAS  Google Scholar 

  27. Carroll JS, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005;122:33–43.

    Article  PubMed  CAS  Google Scholar 

  28. Lin CY, et al. Whole-genome cartography of estrogen receptor a binding sites. PLoS Genet. 2007;3(6):867–85.

    Article  CAS  Google Scholar 

  29. Pradhan M, Bembinster LA, Baumgarten SC, Frasor J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NFκB cooperativity at adjacent response elements. JBC. 2010;285(41):31100–6.

    Article  CAS  Google Scholar 

  30. Frasor J, et al. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell Phenotype. Endocrinology. 2003;144(10):4562–74.

    Article  PubMed  CAS  Google Scholar 

  31. Dalvai M, Bystricky K. Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression. PLoS One. 2010;5(6):e11011.

    Article  PubMed  Google Scholar 

  32. Ohta T, et al. Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction. Br Cancer. 2009;16:268–74.

    Article  Google Scholar 

  33. Edwards SL, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451:1111–6.

    Article  PubMed  CAS  Google Scholar 

  34. Skog S, He Q, Khoshnoud R, Fornander T, Rutqvist LE. Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line. Tumor Biol. 2003;25:41–7.

    Article  Google Scholar 

Download references

Acknowledgments

This work was supported by The National Natural Science Foundation of China (Grant 30870978).

Author information

Authors and Affiliations

  1. Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, 210029, Nanjing, People’s Republic of China

    Wei Ying, Sumeng Wang, Junfeng Shi & Yujie Sun

  2. Department of Cell Biology, Nanjing Medical University, 210029, Nanjing, People’s Republic of China

    Wei Ying, Sumeng Wang, Junfeng Shi & Yujie Sun

  3. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, 210029, Nanjing, People’s Republic of China

    Yujie Sun

Authors
  1. Wei Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sumeng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junfeng Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yujie Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yujie Sun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ying, W., Wang, S., Shi, J. et al. ER−/ER+ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection. Med Oncol 29, 495–502 (2012). https://doi.org/10.1007/s12032-011-9889-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9889-9

Keywords

Search

Navigation